youtube_live
Q3 2026 earnings • in 1 day
See detailschevron_right
QURE:NASDAQ
Uniqure NV
$22.97
arrow_downward
-7.49%(-1.86) 1D
$22.88
arrow_downward
-0.39% (-0.090)todayPre-market
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for QURE...
Open
$26.22
High
$26.60
Low
$22.42
Mkt. cap
1.59B
Avg. vol.
2.94M
Volume
2.39K
52-wk high
$51.72
52-wk low
$8.73
EPS
-$4.05
Beta
1.06
Shares outstanding
69.37M
No. of employees
221
Open
$26.22
High
$26.60
Low
$22.42
Mkt. cap
1.59B
Avg. vol.
2.94M
Volume
2.39K
52-wk high
$51.72
52-wk low
$8.73
EPS
-$4.05
Beta
1.06
Shares outstanding
69.37M
No. of employees
221
News stories
From web sources and news partners
Investor's Business Daily
·
14 hours ago
Uniqure's Reversal Continues; Huntington's Drug Lands At FDA
Benzinga
·
18 hours ago
FDA Pushes uniQure Huntington Therapy Forward, Analyst Brushes Off Softening Signals
Endpoints News
·
19 hours ago
UniQure gets review date and adcomm; Inovia’s stock surges after approval
Investing.com India
·
20 hours ago
Why is uniQure stock sliding today? By Investing.com
Profile
uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies. Wikipedia
About Uniqure NV
Analyst ratings
Based on 9 analysts giving stock ratings to QURE in the past 3 months
Strong buy
Buy
7
Hold
2
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for QURE in the last 3 months.
Highest
Current $22.97
$80.00 (+248.28%)
Average
$51.67 (+124.95%)
Lowest
$28.00 (+21.90%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Patrick Trucchio H.C. Wainwright | Buy | Reiterated | $80.00 | +248.3% | 11/02/2026 |
Joon Lee UBS | Buy | Maintained | $48.00 | +109% | 10/15/2026 |
Unknown Analyst UBS | Buy | Initiated | $48.00 | +109% | 10/14/2026 |
Eliana Merle Barclays | Hold | Downgraded | $28.00 | +21.9% | 10/06/2026 |
Luca Issi RBC Capital | Buy | Reiterated | $48.00 | +109% | 10/02/2026 |
Salveen Richter Goldman Sachs | Hold | Reiterated | $31.00 | +35% | 09/30/2026 |
Yanan Zhu Wells Fargo | Buy | Maintained | $75.00 | +226.5% | 09/29/2026 |
Lachlan Hanbury Brown William Blair | Buy | Maintained | - | - | 09/29/2026 |
Paul Matteis Stifel Nicolaus | Buy | Maintained | - | - | 09/29/2026 |
Joseph Thome TD Cowen | Buy | Maintained | - | - | 09/02/2026 |
Sami Corwin William Blair | Buy | Initiated | $73.00 | +217.8% | 09/02/2026 |
Uy Ear Mizuho Securities | Buy | Reiterated | $68.00 | +196% | 07/29/2026 |
Rudy Li Wolfe Research | Buy | Upgraded | $65.00 | +183% | 07/29/2026 |
Joseph Schwartz Leerink Partners | Buy | Reiterated | $70.00 | +204.7% | 06/17/2026 |
Kristen Kluska Cantor Fitzgerald | Buy | Upgraded | - | - | 06/17/2026 |
Daniil Gataulin Chardan Capital | Buy | Reiterated | $37.00 | +61.1% | 05/05/2026 |
Unknown Analyst Guggenheim | Buy | Maintained | $95.00 | +313.6% | 05/05/2026 |
Next call in 25:49:11
Wed, Nov 4, 8:30 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (EUR)
- GAAP EPS / Est. (EUR)
- / -€0.82
Revenue / Est. (EUR)
- / 5.43M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 3.70M | 5.57M | 3.56M | 5.84M |
Cost of goods sold | 32.25M | 40.18M | 30.73M | 30.66M |
Cost of revenue | 32.25M | 40.18M | 30.73M | 30.66M |
Research and development expenses | 695.00K | -5.92M | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 19.44M | 21.61M | 20.07M | 19.77M |
Operating expense | 20.67M | 15.55M | 19.89M | 26.13M |
Total operating expenses | 52.91M | 55.73M | 50.62M | 56.79M |
Operating income | -49.21M | -50.16M | -47.06M | -50.95M |
Other non operating income | -7.22M | 18.13M | 3.77M | -15.97M |
EBT including unusual items | -71.90M | -41.00M | -53.05M | -79.22M |
EBT excluding unusual items | -70.08M | -40.05M | -54.38M | -77.96M |
Income tax expense | 8.63M | -3.92M | 488.00K | 1.84M |
Effective tax rate | -12.00% | 9.55% | -0.92% | -2.32% |
Other operating expenses | 534.00K | -143.00K | -181.00K | 6.36M |
Net income | -80.53M | -37.09M | -53.54M | -81.06M |
Net profit margin | -2,175.87% | -666.06% | -1,502.95% | -1,387.76% |
Earnings per share | - | - | - | - |
Interest and investment income | 3.50M | 5.81M | 5.23M | 5.05M |
Interest expense | -16.72M | -14.57M | -14.03M | -14.37M |
Net interest expenses | -13.22M | -8.76M | -8.80M | -9.32M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -45.58M | -47.19M | -44.10M | -46.04M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events